UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release

Journal of hypertension, 2016-05, Vol.34 (5), p.869-876

2016

Volltextzugriff (PDF)

Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications

Biochemical and biophysical research communications, 2018-09, Vol.503 (1), p.21-25

2018

Volltextzugriff (PDF)

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

Current medical research and opinion, 2012-04, Vol.28 (4), p.513-523

2012

Volltextzugriff (PDF)

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

Frontiers in immunology, 2022-03, Vol.13, p.843480

2022

Volltextzugriff (PDF)

Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice

European journal of pharmacology, 2019-09, Vol.859, p.172521-172521, Article 172521

2019

Volltextzugriff (PDF)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2020-03, Vol.13 (2), p.156-160

2020

Volltextzugriff (PDF)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo

Journal of pharmacological sciences, 2017-11, Vol.135 (3), p.126-130

2017

Volltextzugriff (PDF)

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial

Endocrine Connections, 2019-04, Vol.8 (4), p.318-325

2019

Volltextzugriff (PDF)

Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine – Review

Stem cell reviews and reports, 2022, Vol.18 (1), p.56-76

2022

Volltextzugriff (PDF)

Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats

Journal of pharmacological sciences, 2016-09, Vol.132 (1), p.65-70

2016

Volltextzugriff (PDF)

Phytosterol supplements do not inhibit dipeptidyl peptidase-4

Diabetes & metabolic syndrome clinical research & reviews, 2020-09, Vol.14 (5), p.1475-1478

2020

Volltextzugriff (PDF)

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia

Diabetes, obesity & metabolism, 2008-08, Vol.10 (8), p.675-682

2008

Volltextzugriff (PDF)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy

Chinese medical journal, 2018-11, Vol.131 (22), p.2658-2665

2018

Volltextzugriff (PDF)

The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor

Annales d'endocrinologie, 2020-10, Vol.81 (5), p.476-481

2020

Volltextzugriff (PDF)

Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan

Pharmacoepidemiology and drug safety, 2015-06, Vol.24 (6), p.567-575

2015

Volltextzugriff (PDF)

Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

Diabetes, obesity & metabolism, 2008-10, Vol.10 (10), p.931-938

2008

Volltextzugriff (PDF)

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

Frontiers in endocrinology (Lausanne), 2019-02, Vol.10, p.80-80

Deacon, Carolyn F

2019

Volltextzugriff (PDF)

Coronavirus Infections and Type 2 Diabetes—Shared Pathways with Therapeutic Implications

Endocrine reviews, 2020-06, Vol.41 (3), p.457-470

Drucker, Daniel J

2020

Volltextzugriff (PDF)

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study

Circulation (New York, N.Y.), 2019-06, Vol.139 (25), p.2822-2830

2019

Volltextzugriff (PDF)

Natural Garlic Organosulfur Compounds Prevent Metabolic Disorder of Lipid and Glucose by Increasing Gut Commensal Bacteroides acidifaciens

Journal of agricultural and food chemistry, 2022-05, Vol.70 (19), p.5829-5837

2022

Volltextzugriff (PDF)

Role of dipeptidyl peptidase-4 and its inhibitor in the respiratory diseases

Zhong nan da xue xue bao. Journal of Central South University. Yi xue ban, 2017-01, Vol.42 (1), p.108-112

2017

Volltextzugriff (PDF)

DPP-4 inhibition: А novel therapeutic approach to the treatment of pulmonary hypertension?

Pharmacology & therapeutics (Oxford), 2019-09, Vol.201, p.1-7

2019

Volltextzugriff (PDF)

Clinical characteristics and outcomes of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid patients: A retrospective study

Journal of the American Academy of Dermatology, 2024-10

2024

Volltextzugriff (PDF)

Linagliptin decreased the tumor progression on glioblastoma model

Biochemical and biophysical research communications, 2024-06, Vol.711, p.149897, Article 149897

2024

Volltextzugriff (PDF)

Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes

Endocrine Journal, 2014, Vol.61(5), pp.513-521

2014

Volltextzugriff (PDF)

1 – 25 von 1.453

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.213)
Mit Volltextzugriff
(1.242)

Publikationsform

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.226)
Life Sciences & Biomedicine
(1.212)
Humans
(665)
Diabetes
(542)
Diabetes Mellitus, Type 2 - Drug Therapy
(494)
Endocrinology & Metabolism
(477)
Dipeptidyl Peptidase-4 Inhibitor
(476)
Dipeptidyl Peptidase-4 Inhibitors
(438)
Dipeptidyl Peptidase-4
(437)
Type 2 Diabetes
(409)
Male
(394)
Diabetes Mellitus
(376)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(343)
Pharmacology & Pharmacy
(298)
Female
(295)
Hypoglycemic Agents - Therapeutic Use
(287)
Type 2 Diabetes Mellitus
(285)
Middle Aged
(251)
Animals
(227)
Glucose
(215)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release

Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial

Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine – Review

Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats

Phytosterol supplements do not inhibit dipeptidyl peptidase-4

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy

The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor

Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan

Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

Coronavirus Infections and Type 2 Diabetes—Shared Pathways with Therapeutic Implications

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study

Natural Garlic Organosulfur Compounds Prevent Metabolic Disorder of Lipid and Glucose by Increasing Gut Commensal Bacteroides acidifaciens

Role of dipeptidyl peptidase-4 and its inhibitor in the respiratory diseases

DPP-4 inhibition: А novel therapeutic approach to the treatment of pulmonary hypertension?

Clinical characteristics and outcomes of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid patients: A retrospective study

Linagliptin decreased the tumor progression on glioblastoma model

Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes

Suchergebnisse filtern